Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Headache Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Eur J Pain. 2021 Nov;25(10):2177-2189. doi: 10.1002/ejp.1831. Epub 2021 Jul 13.
Clinical guidelines agree that preventive treatment should be considered in patients with uncontrolled migraine despite acute medications or patients with ≥4 migraine days per month. However, the criteria to define the effectiveness of treatment and the factors that inform the decision to (dis)continue it are not clearly defined in clinical practice.
Overall, 148 healthcare practitioners from five European countries completed a two-wave questionnaire. The Steering Committee defined a simulated set of 108 migraine patient profiles based on the combination of five factors (frequency of the attacks, intensity of the attacks, use of acute migraine medications, patient perception and presence/absence of tolerable side effects). These profiles were used in a Delphi survey among European neurologists to identify the criteria that should be used to decide treatment response and continuation using a conjoint analysis approach.
Consensus was reached for 82/108 (76%) of profiles regarding treatment response, and for 86/108 (80%) regarding treatment continuation. Multivariable logistic regression analysis showed that a ≥50% reduction in the use of acute migraine medications and positive patient's perception of treatment were the most important factors that lead to the decision of continuing (combined factors, OR = 18.3, 95% CI 13.4-25.05).
This survey identifies two relevant outcome measures: one objective (use of acute migraine treatment medications) and one subjective (positive patient perception) that guide the clinician decision to continue preventive treatment in migraine patients.
In clinical practice, criteria to define the effectiveness of migraine preventive treatment and factors that guide treatment stop or continuation are not clearly defined. In this simulated clinical setting study, a reduction in the use of acute migraine medications was the factor associated with preventive treatment effectiveness definition. This study also revealed that factors strongly associated with the decision of treatment continuation in real life are the acute migraine medications use and a positive patient's perception of treatment effectiveness.
临床指南一致认为,对于急性药物治疗仍无法控制的偏头痛患者或每月偏头痛发作天数≥4 天的患者,应考虑预防性治疗。然而,在临床实践中,尚未明确界定治疗有效性的标准以及决定(停止)治疗的依据。
来自五个欧洲国家的 148 名医疗保健专业人员完成了两波问卷调查。指导委员会根据五个因素(发作频率、发作强度、急性偏头痛药物使用、患者感知以及可耐受副作用的存在/缺失)的组合,定义了一组模拟的 108 个偏头痛患者病例。这些病例在欧洲神经病学家中进行了 Delphi 调查,以确定使用联合分析方法来决定治疗反应和继续治疗的标准。
82/108(76%)个病例在治疗反应方面达成共识,86/108(80%)个病例在治疗继续方面达成共识。多变量逻辑回归分析显示,急性偏头痛药物使用量减少≥50%和患者对治疗的积极感知是决定继续治疗的最重要因素(综合因素,OR=18.3,95%CI 13.4-25.05)。
本调查确定了两个相关的结果衡量标准:一个是客观的(急性偏头痛治疗药物的使用),另一个是主观的(患者对治疗的积极感知),这两个标准指导临床医生在偏头痛患者中决定继续预防性治疗。
在临床实践中,尚未明确界定偏头痛预防性治疗有效性的标准以及指导治疗停止或继续的依据。在这个模拟临床环境的研究中,急性偏头痛药物使用量的减少是与预防性治疗有效性定义相关的因素。该研究还表明,与治疗继续决策密切相关的因素是急性偏头痛药物的使用和患者对治疗效果的积极感知。